Oncology News Articles

▼ Show details

The latest Cancer and Oncology news articles published daily by MDLinx physician editors who comb through the top peer-reviewed clinical journals for the medical articles that will make a difference to you and your practice. Organized by topic including breast, hematologic, thoracic, gastrointestinal and genitourinary cancers. In a matter of minutes, oncologists, oncology nurses, physician assistants can stay current on latest oncology topics, symptoms, treatments, risk factors in Cancer and Hematology.

New! >> Start your free Oncology Board Exam Prep course now.
Ranked, sorted, and summarized by MDLinx editors from the latest literature
Topics:

1 Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: A prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial The Lancet Oncology, October 24, 2014    Clinical Article

2 Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline Journal of Clinical Oncology, October 24, 2014    Clinical Guideline

3 Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL) European Journal of Haematology, October 24, 2014    Clinical Article

4 Anti-angiogenic therapy versus dose-dense paclitaxel therapy for frontline treatment of epithelial ovarian cancer: Review of phase III randomized clinical trials Current Oncology Reports, October 24, 2014    Review Article

5 Preliminary results of a phase II trial of proton radiotherapy for pediatric rhabdomyosarcoma Journal of Clinical Oncology, October 24, 2014    Clinical Article

6 Treatment-related fatigue with everolimus and temsirolimus in patients with cancer—a meta-analysis of clinical trials Tumor Biology, October 24, 2014    Evidence Based Medicine

7 Evidence of differential effects of vitamin D receptor variants on epithelial ovarian cancer risk by predicted vitamin D status Frontiers in Oncology, October 24, 2014    Clinical Article

8 Tumor marker usage and medical care costs among older early-stage breast cancer survivors Journal of Clinical Oncology, October 24, 2014    Clinical Article

9 Serum galactomannan vs a combination of galactomannan and PCR-based aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: A randomized controlled trial Clinical Infectious Diseases, October 24, 2014    Clinical Article

10 Mathematical models for diffusion-weighted imaging of prostate cancer using b values up to 2000 s/mm2: Correlation with Gleason score and repeatability of region of interest analysis Magnetic Resonance in Medicine, October 24, 2014    Clinical Article

11 Thyroid cancer mortality and incidence: A global overview International Journal of Cancer, October 24, 2014    Clinical Article

12 Psychosocial adjustments in patients with prostate cancer from pre-diagnosis to 6 months post-treatment International Journal of Nursing Practice, October 24, 2014    Clinical Article

13 Statin use and risk of nonmelanoma skin cancer: a nationwide study in Denmark British Journal of Cancer, October 24, 2014    Clinical Article

14 Serum copper is a simple but valuable prognostic marker in B-cell chronic lymphocytic leukemia International Journal of Hematology, October 24, 2014    Clinical Article

15 Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease Clinical Cancer Research, October 24, 2014    Clinical Article

16 New strategies in chronic lymphocytic leukemia: shifting treatment paradigms Clinical Cancer Research, October 24, 2014    Clinical Article

17 Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer Clinical Cancer Research, October 24, 2014    Clinical Article

18 MiR-204-5p inhibits proliferation and invasion and enhances chemotherapeutic sensitivity of colorectal cancer cells by down-regulating RAB22A Clinical Cancer Research, October 24, 2014    Clinical Article

19 Breast cancer incidence and mortality in a transitioning Chinese population: current and future trends British Journal of Cancer, October 24, 2014    Clinical Article

20 Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study British Journal of Cancer, October 24, 2014    Clinical Article

50 available pages FirstPrevious 1 2 3 4 5 6 7 8 9 10 Next Last

Clinical Pearls in Oncology

Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Highlights in Oncology

Immunophenotype of small intestinal adenocarcinoma predicts survival

As reported in the European Journal of Obstetrics and Gynecology & Reproductive Biology, levels of the adipokine, apelin, are decreased in women with PCOS (n=45) compared to healthy controls. Apelin levels are positively correlated with BMI, insulin levels, triglycerides levels, free testosterone levels, the Ferriman-Gallwey score, and the HOMA index. Apelin levels are negatively correlated with HDL levels.

CHD7 associated with survival in pancreatic ductal adenocarcinoma patients receiving gemcitabine

As reported in Cancer Research, low CHD7 expression is associated with increased RFS and OS in pancreatic ductal adenocarcinoma patients receiving gemcitabine. There was no association between CHD7 expression and RFS or OS in patients who were not treated with gemcitabine.

CTC count predicts survival in mBC

As reported in The Lancet Oncology, circulating tumor cell (CTC) quantification in patients (20 studies; n = 1944) with metastatic breast cancer (mBC) predicts progression-free survival (PFS) and overall survival (OS), especially when coupled with clinicopathologic data. A CTC count ≥ 5/7.5 mL at baseline is associated with decreased PFS (HR = 1.92) and OS (HR = 2.78). An elevated CTC count 3-5 weeks and 6-8 weeks after treatment commences is also associated with decreased PFS (HR = 1.85 and 2.20) and OS (HR = 2.26 and 2.91).


Other Topics in Oncology

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close